Page last updated: 2024-10-30

metformin and Liver Cirrhosis

metformin has been researched along with Liver Cirrhosis in 77 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Research Excerpts

ExcerptRelevanceReference
"Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated."9.11A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005)
"A PubMed (1946-August 2013) search using the keywords type 2 diabetes mellitus, metformin, hepatitis C virus, cirrhosis, and hepatocellular carcinoma was conducted."8.89Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013)
"The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study."8.31Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023)
" The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before."8.31Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023)
"Metformin use was associated with higher risks of mortality and cirrhotic decompensation in patients with compensated liver cirrhosis."8.12Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. ( Hou, MC; Hsu, CC; Huang, YH; Hwu, CM; Lo, YR; Shin, SJ; Yen, FS, 2022)
"To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients."7.78Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. ( Ampuero, J; Bautista, JD; Camacho, I; del Campo, JA; Díaz-Herrero, Mdel M; Figueruela, B; Maraver, M; Nuñez, D; Ranchal, I; Rojas, Á; Romero-Gómez, M, 2012)
"Liver fibrosis is a disease with significant morbidity and mortality."7.01Research progress of metformin in the treatment of liver fibrosis. ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023)
"Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide."6.90Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. ( Duława, J; Handzlik, G; Holecki, M; Kędzierski, L; Kozaczka, J; Kukla, M; Pawlicki, K; Wyskida, K, 2019)
"Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters."6.82Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016)
"Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods."5.43Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016)
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes."5.38Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012)
"Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated."5.11A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005)
"A PubMed (1946-August 2013) search using the keywords type 2 diabetes mellitus, metformin, hepatitis C virus, cirrhosis, and hepatocellular carcinoma was conducted."4.89Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. ( Harris, K; Smith, L, 2013)
"The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study."4.31Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. ( Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chung, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML, 2023)
" The potential protective outcome of the antidiabetic and pleiotropic drug metformin against TAA-induced chronic kidney disease in association with the modulation of AMP-activated protein kinase (AMPK), oxidative stress, inflammation, dyslipidemia, and systemic hypertension has not been investigated before."4.31Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension. ( Al-Ani, B; Albawardi, A; Alqahtani, SM; Alshahrani, MY; Bayoumy, NM; Ebrahim, HA; Haidara, MA; Kamar, SS; ShamsEldeen, AM, 2023)
"Metformin use was associated with higher risks of mortality and cirrhotic decompensation in patients with compensated liver cirrhosis."4.12Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. ( Hou, MC; Hsu, CC; Huang, YH; Hwu, CM; Lo, YR; Shin, SJ; Yen, FS, 2022)
"Metformin use in patients with cirrhosis and diabetes appears safe and is associated independently with reduced overall, but not liver-related, mortality, hepatocellular carcinoma, or decompensation after adjusting for concomitant statin and angiotensinogen-converting enzyme inhibitor/angiotensin-2-receptor blocker exposure."4.02Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. ( Albrecht, J; Aytaman, A; Baytarian, M; Fox, R; Hunt, K; John, BV; Kaplan, DE; Lerer, R; Mehta, R; Serper, M; Taddei, TH; Tessiatore, KM, 2021)
"Our study demonstrated an association between long-term metformin use and reduced the risk of all-cause mortality/transplant and hepatocellular carcinoma in diabetics with non-alcoholic steatohepatitis and advanced fibrosis."3.91Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. ( Chalasani, N; Cummings, OW; Desai, AP; Gawrieh, S; Ghabril, M; Saxena, R; Vilar-Gomez, E; Vuppalanchi, R, 2019)
"To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients."3.78Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. ( Ampuero, J; Bautista, JD; Camacho, I; del Campo, JA; Díaz-Herrero, Mdel M; Figueruela, B; Maraver, M; Nuñez, D; Ranchal, I; Rojas, Á; Romero-Gómez, M, 2012)
"A total of 100 consecutive diabetic patients (53 men, age 61 ± 11 yr) with ongoing HCV cirrhosis and no contraindication for metformin were included in a screening program for hepatocellular carcinoma (HCC)."3.77Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. ( Aout, M; Beaugrand, M; Bourcier, V; Charif, I; Cosson, E; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Trinchet, JC; Vicaut, E, 2011)
"Liver fibrosis is a disease with significant morbidity and mortality."3.01Research progress of metformin in the treatment of liver fibrosis. ( Hu, C; Huang, Y; Li, B; Li, Y; Qian, F; Sun, W; Yang, F; Zhang, A, 2023)
"Portal hypertension is the main determinant of clinical decompensation in patients with liver cirrhosis."3.01Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. ( Aagaard, NK; George, J; Grønbaek, H; Jessen, N; Rittig, N; Sandahl, TD; Villadsen, GE, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide."2.90Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. ( Duława, J; Handzlik, G; Holecki, M; Kędzierski, L; Kozaczka, J; Kukla, M; Pawlicki, K; Wyskida, K, 2019)
"Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters."2.82Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016)
"However, most patients with NAFLD/NASH will die from a vascular cause."2.72Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021)
"Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children."2.66Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. ( Kohli, R; Lin, CH, 2020)
"Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC)."2.52Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. ( Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S, 2015)
"Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk."2.47[Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011)
"Insulin resistance is considering as having a central role in NAFLD pathogenesis."2.44[Non-alcoholic fatty liver disease--new view]. ( Lawniczak, M; Marlicz, W; Miezyńska-Kurtycz, J; Milkiewicz, P; Raszeja-Wyszomirska, J, 2008)
"Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America."2.44Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007)
"The extent of liver fibrosis, ranging from fibrosis stage (FS) of none (F0) to cirrhosis (F4), is a strong predictor of health outcomes."1.91Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. ( Articolo, A; Charlton, M; Luthra, R; Shelley, K, 2023)
"Metformin can inhibit HSCs; however, no systematic studies demonstrating the effects of metformin on mitochondria in HSCs have been reported."1.91Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis. ( Hou, C; Liu, X; Ren, K; Su, Y; Wang, M; Zhao, S; Zhou, D, 2023)
"At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy."1.72Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). ( Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA, 2022)
"Central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are the major risk factors for NAFLD."1.72Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022)
"Incident ascites was associated with increased risk of death, HR 27."1.72Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ( Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z, 2022)
"The changes that follow liver fibrosis were assessed by measurement of hepatic enzymes (ALT, AST and ALP), histopathological examination using hematoxylin and eosin stain, special stains, and α-smooth muscle actin (α-SMA) immunostaining, measuring oxidative stress markers (MDA, GSH, NOx and MnSOD) and transforming growth factor-beta 1 (TGF-β1) in liver."1.72Metformin versus silymarin as hepatoprotective agents in mice fibrotic model caused by carbon tetrachloride. ( Ahmed, AA; Ahmed, MA; El-Bakry, MH; Hasan, A; Omar, ZMM, 2022)
"The incidence of hepatocellular carcinoma (HCC) in the United Kingdom has increased 60% in the past 10 years."1.72The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival. ( Berhane, S; Cuthbertson, DJ; Dhanaraj, S; Graef, S; Hydes, TJ; Johnson, PJ; Singh, P; Skowronska, A; Tahrani, A; Teng, M, 2022)
"We investigated the evolution of liver fibrosis and steatosis during 2-year use of metformin in patients with T2DM."1.62Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. ( Ahn, SH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Lee, JS; Park, JY, 2021)
"Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading liver disease globally."1.62Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. ( Gawrieh, S; Khneizer, G; Rizvi, S, 2021)
"Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0."1.62Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. ( Adams, LA; Aller-de la Fuente, R; Calzadilla-Bertot, L; Castellanos, M; Eslam, M; George, J; Romero-Gomez, M; Vilar-Gomez, E; Wong, GL; Wong, VW, 2021)
"In our cohort of T2D with biopsy proven NAFLD, the patients who were receiving metformin, liraglutide, lisinopril, hydrochlorothiazide, atorvastatin and simvastatin were less likely to have AF on biopsy, while patients who were receiving furosemide and spironolactone had a higher likelihood of having AF when they underwent liver biopsy."1.56Medications in type-2 diabetics and their association with liver fibrosis. ( Al-Yaman, W; Amin, H; Chadalavada, P; Garg, R; Lopez, R; Siddiqui, MT; Singh, A, 2020)
"Metformin ameliorated steatohepatitis, liver fibrosis, inflammatory cytokine production and decreased α -SMA and GPR91expression in the livers of the MCD diet-fed mice."1.48Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. ( Cho, EH; Choi, DH; Le, CT; Nguyen, G; Park, SY; Park, WS, 2018)
"Metformin is an anti-diabetic agent which possesses anti-inflammation and anti-angiogenesis properties."1.46Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats. ( Chang, CC; Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Ko, MT; Lee, FY; Lee, SD; Lee, WS, 2017)
"Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause."1.46Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017)
"A total of 109 patients who had chronic hepatitis B and were receiving NA therapy were analyzed."1.43Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. ( Arai, K; Honda, M; Kaneko, S; Kawaguchi, K; Mizukoshi, E; Nakamura, M; Oishi, N; Okada, H; Sakai, Y; Shimakami, T; Shirasaki, T; Terashima, T; Wang, X; Yamashita, T, 2016)
"Metformin is an attractive agent for chemoprevention because it is inexpensive, has a favorable safety profile, and is well tolerated over long time periods."1.43Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. ( Chung, RT; DePeralta, DK; Fuchs, BC; Ghoshal, S; Lanuti, M; Lauwers, GY; Schmidt, B; Tanabe, KK; Wei, L, 2016)
"Patients with nonalcoholic steatohepatitis (NASH) had similar demographic and anthropometric features, but a higher prevalence of type 2 diabetes (T2D; p = 0."1.43Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. ( Borroni, V; Bugianesi, E; Craxi, A; Dongiovanni, P; Fargion, S; Fracanzani, AL; Pelusi, S; Petta, S; Rosso, C; Valenti, L, 2016)
"Metformin-treated CCl4-cirrhotic rats had lower PP and hepatic vascular resistance than vehicle-treated rats, without significant changes in MAP or PBF."1.42Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. ( Bosch, J; Erice, E; García-Calderó, H; García-Pagán, JC; Gracia-Sancho, J; Lafoz, E; Sarin, SK; Tripathi, DM, 2015)
"A total of 302/479 (63%) NAFLD patients (mean age: 47 ± 13 year) were included with a follow-up period of 12."1.39NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. ( Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S, 2013)
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes."1.38Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012)

Research

Studies (77)

TimeframeStudies, this research(%)All Research%
pre-19905 (6.49)18.7374
1990's0 (0.00)18.2507
2000's6 (7.79)29.6817
2010's38 (49.35)24.3611
2020's28 (36.36)2.80

Authors

AuthorsStudies
Abdelhamid, AM1
Youssef, ME1
Abd El-Fattah, EE1
Gobba, NA1
Gaafar, AGA1
Girgis, S1
Shata, A1
Hafez, AM1
El-Ahwany, E1
Amin, NA1
Shahien, MA1
Abd-Eldayem, MA1
Abou-Elrous, M1
Saber, S1
Lavynenko, O1
Abdul-Ghani, M1
Alatrach, M1
Puckett, C1
Adams, J1
Abdelgani, S1
Alkhouri, N1
Triplitt, C1
Clarke, GD1
Vasquez, JA1
Li, J8
Cersosimo, E1
Gastaldelli, A1
DeFronzo, RA1
Hydes, TJ1
Cuthbertson, DJ1
Graef, S1
Berhane, S1
Teng, M1
Skowronska, A1
Singh, P1
Dhanaraj, S1
Tahrani, A1
Johnson, PJ1
Omar, ZMM1
Ahmed, AA1
El-Bakry, MH1
Ahmed, MA1
Hasan, A1
Tapper, EB1
Zhao, Z2
Mazumder, N1
Parikh, ND1
Su, Y2
Lu, S1
Hou, C2
Ren, K2
Wang, M2
Liu, X5
Zhao, S3
Zhou, ST1
Cui, W1
Kong, L1
Yang, X3
Tsai, PC1
Kuo, HT1
Hung, CH1
Tseng, KC1
Lai, HC1
Peng, CY1
Wang, JH1
Chen, JJ1
Lee, PL1
Chien, RN1
Yang, CC1
Lo, GH1
Kao, JH1
Liu, CJ1
Liu, CH1
Yan, SL1
Bair, MJ1
Lin, CY1
Su, WW1
Chu, CH2
Chen, CJ1
Tung, SY1
Tai, CM1
Lin, CW1
Lo, CC1
Cheng, PN1
Chiu, YC1
Wang, CC1
Cheng, JS1
Tsai, WL1
Lin, HC1
Huang, YH2
Yeh, ML1
Huang, CF1
Hsieh, MH1
Huang, JF1
Dai, CY1
Chung, WL1
Chen, CY1
Yu, ML1
Zhang, W1
Lv, Y1
Huo, F1
Zhang, Y5
Yin, C1
Zhang, A2
Qian, F1
Li, Y6
Li, B3
Yang, F1
Hu, C1
Sun, W1
Huang, Y2
Zhou, D1
Yang, T3
Guan, Q1
Shi, JS1
Xu, ZH1
Geng, Y1
Alshahrani, MY1
Ebrahim, HA1
Alqahtani, SM1
Bayoumy, NM1
Kamar, SS2
ShamsEldeen, AM1
Haidara, MA2
Al-Ani, B2
Albawardi, A1
Stevens, LJ1
Dubbeld, J1
Doppenberg, JB1
van Hoek, B1
Menke, AL1
Donkers, JM1
Alsharaa, A1
de Vries, A1
Vaes, WHJ1
Knibbe, CAJ1
van de Steeg, E1
Alwayn, IPJ1
Shelley, K1
Articolo, A1
Luthra, R1
Charlton, M1
Ratziu, V1
Pais, R1
Huo, RR1
Liang, JR1
He, FY1
Xu, BR1
Ma, L1
Yuan, WP1
Dogru, T1
Kırık, A1
Sonmez, A1
Vilar-Gomez, E4
Chalasani, N5
Calzadilla-Bertot, L1
Wong, VW1
Castellanos, M1
Aller-de la Fuente, R1
Eslam, M1
Wong, GL1
George, J3
Romero-Gomez, M2
Adams, LA1
Khneizer, G1
Rizvi, S1
Gawrieh, S3
Mahjoubin-Tehran, M1
De Vincentis, A1
Mikhailidis, DP1
Atkin, SL1
Mantzoros, CS1
Jamialahmadi, T1
Sahebkar, A2
Siddiqui, MT1
Amin, H1
Garg, R1
Chadalavada, P1
Al-Yaman, W1
Lopez, R1
Singh, A2
Kaplan, DE2
Serper, M2
John, BV2
Tessiatore, KM1
Lerer, R1
Mehta, R1
Fox, R1
Aytaman, A1
Baytarian, M1
Hunt, K1
Albrecht, J1
Taddei, TH1
Lin, CH1
Kohli, R1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M2
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X11
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A2
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Ren, Y1
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L3
Zhuang, T1
Tu, J1
Qu, Y1
Yao, H1
Wang, X6
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X5
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X2
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K2
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC2
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H2
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L2
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J2
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Lee, HW1
Lee, JS1
Kim, BK1
Park, JY1
Kim, DY1
Ahn, SH1
Kim, SU1
Rittig, N2
Aagaard, NK2
Villadsen, GE2
Sandahl, TD2
Jessen, N2
Grønbaek, H2
Yen, FS1
Hou, MC1
Hwu, CM1
Lo, YR1
Shin, SJ1
Hsu, CC1
Saffo, S1
Mahmud, N1
Ross, JS1
Taddei, T1
Harlow, KE1
Pike, F1
Yates, KP1
Wilson, LA1
Cummings, OW2
Rosenberg, WM1
Molleston, JP1
Fan, K1
Lin, L1
Ge, P1
Dai, J1
Hu, K1
Ko, MT1
Huang, HC1
Lee, WS1
Chuang, CL1
Hsin, IF1
Hsu, SJ1
Lee, FY1
Lee, SD1
Liu, CW1
Yang, YY1
Nguyen, G1
Park, SY2
Le, CT1
Park, WS1
Choi, DH1
Cho, EH1
Caussy, C1
Hsu, C1
Lo, MT1
Liu, A1
Bettencourt, R1
Ajmera, VH1
Bassirian, S1
Hooker, J1
Sy, E1
Richards, L1
Schork, N1
Schnabl, B1
Brenner, DA1
Sirlin, CB1
Chen, CH1
Loomba, R2
Dong, G1
Lin, X1
Gao, D1
Ren, Z1
Chen, R1
Al-Hashem, F1
Al-Humayed, S1
Amin, SN1
Mansy, SS1
Hassan, S1
Abdel-Salam, LO1
Ellatif, MA1
Alfaifi, M1
Handzlik, G1
Holecki, M1
Kozaczka, J1
Kukla, M1
Wyskida, K1
Kędzierski, L1
Pawlicki, K1
Duława, J1
Jiao, Y1
Xing, Y1
Gao, P1
Das, BK1
Choukimath, SM1
Gadad, PC1
Vuppalanchi, R2
Desai, AP1
Ghabril, M1
Saxena, R1
Ianiro, G1
Ponziani, FR1
Gasbarrini, A1
Cammarota, G1
Treeprasertsuk, S1
Björnsson, E1
Enders, F1
Suwanwalaikorn, S1
Lindor, KD1
Harris, K1
Smith, L1
Harmsen, WS1
Mettler, TA1
Kim, WR1
Roberts, RO1
Therneau, TM1
Roberts, LR1
Chaiteerakij, R1
Pariente, A1
Katsura, A1
Morishita, A1
Iwama, H1
Tani, J1
Sakamoto, T1
Tatsuta, M1
Toyota, Y1
Fujita, K1
Kato, K2
Maeda, E1
Nomura, T1
Miyoshi, H1
Yoneyama, H1
Himoto, T1
Fujiwara, S1
Kobara, H1
Mori, H1
Niki, T1
Ono, M1
Hirashima, M1
Masaki, T1
Jung, GS1
Jeon, JH1
Choi, YK1
Jang, SY1
Kim, MK1
Shin, EC1
Jeong, WI1
Lee, IK1
Kang, YN1
Park, KG1
Tripathi, DM1
Erice, E1
Lafoz, E1
García-Calderó, H1
Sarin, SK1
Bosch, J1
Gracia-Sancho, J1
García-Pagán, JC1
Traussnigg, S1
Kienbacher, C1
Halilbasic, E1
Rechling, C1
Kazemi-Shirazi, L1
Hofer, H1
Munda, P1
Trauner, M1
Honda, M1
Shirasaki, T1
Terashima, T1
Kawaguchi, K1
Nakamura, M1
Oishi, N1
Shimakami, T1
Okada, H1
Arai, K1
Yamashita, T2
Sakai, Y1
Mizukoshi, E1
Kaneko, S2
DePeralta, DK1
Ghoshal, S1
Schmidt, B1
Lauwers, GY1
Lanuti, M1
Chung, RT1
Tanabe, KK1
Fuchs, BC1
Elkrief, L1
Rautou, PE1
Sarin, S1
Valla, D1
Paradis, V1
Moreau, R1
Doyle, MA1
Singer, J1
Lee, T1
Muir, M1
Cooper, C1
Shen, C1
Peng, C1
Shen, B1
Zhu, Z1
Xu, N1
Li, T1
Xie, J1
Pelusi, S1
Petta, S1
Rosso, C1
Borroni, V1
Fracanzani, AL1
Dongiovanni, P1
Craxi, A1
Bugianesi, E2
Fargion, S1
Valenti, L1
Kasmari, AJ1
Welch, A1
Liu, G1
Leslie, D1
McGarrity, T1
Riley, T1
Raszeja-Wyszomirska, J1
Lawniczak, M1
Marlicz, W1
Miezyńska-Kurtycz, J1
Milkiewicz, P1
González Jiménez, E1
Schmidt Río-Valle, J1
Álvarez Ferre, J1
Nkontchou, G1
Cosson, E1
Aout, M1
Mahmoudi, A1
Bourcier, V1
Charif, I1
Ganne-Carrie, N1
Grando-Lemaire, V1
Vicaut, E1
Trinchet, JC1
Beaugrand, M1
Popov, VB1
Lim, JK1
Kita, Y1
Takamura, T1
Misu, H1
Ota, T1
Kurita, S1
Takeshita, Y1
Uno, M1
Matsuzawa-Nagata, N1
Ando, H1
Fujimura, A1
Hayashi, K1
Kimura, T1
Ni, Y1
Otoda, T1
Miyamoto, K1
Zen, Y1
Nakanuma, Y1
Ampuero, J1
Ranchal, I1
Nuñez, D1
Díaz-Herrero, Mdel M1
Maraver, M1
del Campo, JA1
Camacho, I1
Figueruela, B1
Bautista, JD1
Gentilcore, E1
Manini, R1
Natale, S1
Vanni, E1
Villanova, N1
David, E1
Rizzetto, M1
Marchesini, G1
Kluwe, J1
Lohse, AW1
Kadayifci, A1
Merriman, RB1
Hoteit, MA1
Anania, FA1
Selvini, A1
Brugi, A1
Emanueli, A1
Streda, M2
Gormsen, J2
Laursen, B1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451]Phase 1/Phase 2120 participants (Actual)Interventional2020-07-27Completed
Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT04182321]60 participants (Actual)Interventional2020-03-13Completed
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]Phase 2112 participants (Anticipated)Interventional2021-08-03Recruiting
Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.[NCT02306070]Phase 20 participants (Actual)Interventional2016-01-31Withdrawn (stopped due to insufficient funding)
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571]1,080 participants (Anticipated)Observational2019-04-01Recruiting
PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort[NCT02319200]Phase 311 participants (Actual)Interventional2015-06-30Terminated (stopped due to Decision of investigator)
Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806]Phase 415 participants (Anticipated)Interventional2022-10-10Active, not recruiting
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]Phase 28 participants (Actual)Interventional2012-04-30Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018]Phase 2/Phase 390 participants (Actual)Interventional2003-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

14 reviews available for metformin and Liver Cirrhosis

ArticleYear
Research progress of metformin in the treatment of liver fibrosis.
    International immunopharmacology, 2023, Volume: 116

    Topics: Fibrosis; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Metformin

2023
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Molecular metabolism, 2021, Volume: 50

    Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di

2021
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
    Current gastroenterology reports, 2020, Aug-19, Volume: 22, Issue:10

    Topics: Adolescent; Alanine Transaminase; Antioxidants; Bariatric Surgery; Child; Child, Preschool; Cysteami

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.
    BioMed research international, 2019, Volume: 2019

    Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Glucose; Hepacivirus; Hepatitis B; Hepatitis

2019
Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:10

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatitis C, Chronic; Humans; Hypoglycemic Age

2013
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4

    Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progre

2015
Diabetes mellitus in patients with cirrhosis: clinical implications and management.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:7

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hypoglycemic Agents; I

2016
[Non-alcoholic fatty liver disease--new view].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 24, Issue:144

    Topics: Biopsy; Causality; Comorbidity; Disease Progression; Fatty Liver; Humans; Hyperglycemia; Insulin Res

2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type

2009
[Fatty liver and its clinical management in obese adolescents].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:1

    Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros

2011
[Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
    Der Internist, 2005, Volume: 46, Issue:12

    Topics: Diet Therapy; Exercise Therapy; Fatty Liver; Fatty Liver, Alcoholic; Humans; Liver Cirrhosis; Liver

2005
Treatment of fibrosis in nonalcoholic fatty liver disease.
    Current gastroenterology reports, 2007, Volume: 9, Issue:1

    Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age

2007
Glucose tolerance tests in the clinical picture of chronic liver diseases.
    Acta Universitatis Carolinae. Medica. Monographia, 1975, Issue:67

    Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight

1975

Trials

6 trials available for metformin and Liver Cirrhosis

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.
    Alimentary pharmacology & therapeutics, 2021, Volume: 54, Issue:3

    Topics: Humans; Hypertension, Portal; Liver Cirrhosis; Metformin; Portal Pressure

2021
Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin.
    The Journal of pediatrics, 2021, Volume: 239

    Topics: Adolescent; Area Under Curve; Biopsy; Child; Double-Blind Method; Drug Therapy, Combination; Female;

2021
Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:2

    Topics: Adult; Blood Cell Count; Combined Modality Therapy; Elasticity Imaging Techniques; Female; Humans; H

2019
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005

Other Studies

58 other studies available for metformin and Liver Cirrhosis

ArticleYear
Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride.
    Life sciences, 2021, Dec-01, Volume: 286

    Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Carbon Tetrachloride

2021
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:5

    Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty

2022
The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival.
    Clinical therapeutics, 2022, Volume: 44, Issue:2

    Topics: Carcinoma, Hepatocellular; Child; Diabetes Mellitus, Type 2; Glucose; Humans; Incidence; Liver Cirrh

2022
Metformin versus silymarin as hepatoprotective agents in mice fibrotic model caused by carbon tetrachloride.
    Annales pharmaceutiques francaises, 2022, Volume: 80, Issue:5

    Topics: Animals; Antioxidants; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Liver; Liver Ci

2022
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:11

    Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Huma

2022
Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin.
    International immunopharmacology, 2022, Volume: 108

    Topics: Animals; Apoptosis; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Metformin; Mice; Mitochondria; N

2022
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Current medical science, 2022, Volume: 42, Issue:3

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat;

2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    Journal of hepatology, 2023, Volume: 78, Issue:2

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Mellitus; Hepatitis C, C

2023
Viscosity-sensitive NIR probe for
    Journal of materials chemistry. B, 2022, 11-09, Volume: 10, Issue:43

    Topics: Fluorescent Dyes; Humans; Liver Cirrhosis; Metformin; Viscosity

2022
Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis.
    The international journal of biochemistry & cell biology, 2023, Volume: 157

    Topics: Adenosine Triphosphate; DNA, Mitochondrial; Electron Transport; Energy Metabolism; Hepatic Stellate

2023
Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF-1 in the gut microbiota.
    Biochimica et biophysica acta. Molecular basis of disease, 2023, Volume: 1869, Issue:5

    Topics: Animals; Gastrointestinal Microbiome; Lactobacillus; Lipopolysaccharides; Liver Cirrhosis; Metformin

2023
Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension.
    Molecules (Basel, Switzerland), 2023, Mar-18, Volume: 28, Issue:6

    Topics: AMP-Activated Protein Kinases; Animals; Down-Regulation; Dyslipidemias; Fibrosis; Hypertension; Infl

2023
Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function.
    Clinical pharmacology and therapeutics, 2023, Volume: 114, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Digoxin; Drug Interactions; Furosemide; Hep

2023
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    BMC gastroenterology, 2023, May-19, Volume: 23, Issue:1

    Topics: Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA R

2023
Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:5

    Topics: Diabetes Mellitus; Humans; Incretins; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease

2019
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:7

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Ne

2019
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:7

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin; N

2019
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:7

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin; N

2019
Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:7

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Liver Cirrhosis; Liver Neoplasms; Metformin

2019
Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021, Volume: 19, Issue:1

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Liver Neoplasms; Metf

2021
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
    Advances in experimental medicine and biology, 2021, Volume: 1307

    Topics: Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease

2021
Medications in type-2 diabetics and their association with liver fibrosis.
    World journal of gastroenterology, 2020, Jun-21, Volume: 26, Issue:23

    Topics: Biopsy; Diabetes Mellitus, Type 2; Female; Humans; Liver; Liver Cirrhosis; Male; Metformin; Middle A

2020
Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021, Volume: 19, Issue:10

    Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Liver Neoplasms; Metf

2021
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years.
    Journal of diabetes and its complications, 2021, Volume: 35, Issue:1

    Topics: Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Liver Cirrhosis; Male; Metformin; Middle Aged

2021
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Cirrhosis; Metformin; Proportional Haz

2022
Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:10

    Topics: Ascites; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Huma

2021
Editorial: metformin for portal hypertension-old dog, new tricks? Authors' reply.
    Alimentary pharmacology & therapeutics, 2021, Volume: 54, Issue:3

    Topics: Humans; Hypertension, Portal; Liver Cirrhosis; Metformin

2021
Metformin mitigates carbon tetrachloride-induced TGF-β1/Smad3 signaling and liver fibrosis in mice.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 90

    Topics: Actins; Animals; Antioxidants; Carbon Tetrachloride; Collagen Type I; Heme Oxygenase-1; Hepatic Stel

2017
Metformin reduces intrahepatic fibrosis and intrapulmonary shunts in biliary cirrhotic rats.
    Journal of the Chinese Medical Association : JCMA, 2017, Volume: 80, Issue:8

    Topics: AMP-Activated Protein Kinases; Animals; Cyclooxygenase 1; Hepatopulmonary Syndrome; Liver Cirrhosis;

2017
Dual organ beneficial effects of metformin in cirrhotic rats with hepatopulmonary syndrome.
    Journal of the Chinese Medical Association : JCMA, 2017, Volume: 80, Issue:8

    Topics: Animals; Hepatopulmonary Syndrome; Liver Cirrhosis; Metformin; Rats

2017
Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
    Biochemical and biophysical research communications, 2018, 01-22, Volume: 495, Issue:4

    Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Down-Regulation; Hepatic Stellate Cells; Human

2018
Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:3

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Gastrointestinal Microbiome; Humans; Liver Cirrhosis;

2018
Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15.
    Experimental cell research, 2018, 09-15, Volume: 370, Issue:2

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fibrosis; Growth Dif

2018
Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations.
    Journal of cellular physiology, 2019, Volume: 234, Issue:6

    Topics: Animals; Biomarkers; Chronic Disease; Hepatocytes; Hypoxia-Inducible Factor 1, alpha Subunit; Inflam

2019
Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
    Life sciences, 2019, Aug-01, Volume: 230

    Topics: Allylbenzene Derivatives; Animals; Anisoles; Carcinoma, Hepatocellular; Diabetes Mellitus, Experimen

2019
Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:3

    Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Liver

2019
Letter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism?
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:4

    Topics: Diabetes Mellitus; Fibrosis; Humans; Liver; Liver Cirrhosis; Metformin; Microbiota; Non-alcoholic Fa

2019
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    World journal of gastroenterology, 2013, Feb-28, Volume: 19, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Te

2013
Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:6

    Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Liver Cirrhosi

2014
Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: pleiotropic effects hypothesis.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:6

    Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Metformin

2014
[Do not stop metformin when the patient is cirrhotic].
    La Revue du praticien, 2014, Volume: 64, Issue:6

    Topics: Cause of Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Cirrhosis; Metformin;

2014
MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.
    International journal of molecular medicine, 2015, Volume: 35, Issue:4

    Topics: Animals; Choline Deficiency; Cluster Analysis; Diet; Disease Models, Animal; Gene Expression; Gene E

2015
Small heterodimer partner attenuates profibrogenic features of hepatitis C virus-infected cells.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:10

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Cell Line, Tumor; Gluconeogenesis; Hepaci

2015
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
    American journal of physiology. Gastrointestinal and liver physiology, 2015, Sep-01, Volume: 309, Issue:5

    Topics: Animals; Blood Pressure; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Metformin; Portal Vein;

2015
Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    The Journal of infectious diseases, 2016, Apr-01, Volume: 213, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hepatitis B Core

2016
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
    Cancer, 2016, Apr-15, Volume: 122, Issue:8

    Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Hepatocellular; Cell Transformation, Neoplast

2016
Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line

2016
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme

2016
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
    The American journal of medicine, 2017, Volume: 130, Issue:6

    Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human

2017
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:8

    Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C,

2011
Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:8

    Topics: Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Metformin

2011
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Animals; Cluster Analysis; Disease Models, Animal; Fatty Liver; Gene Expression Profiling; Gene Expr

2012
Metformin inhibits glutaminase activity and protects against hepatic encephalopathy.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Age Factors; Ammonia; Diabetes Complications; Enzyme Inhibitors; Female; Glutaminase; Hepatic Enceph

2012
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2006
[On the use of ER 102 in the treatment of diabetes mellitus].
    Minerva medica, 1967, Jan-24, Volume: 58, Issue:7

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus; Female; Humans; Insulin; Liver Cirrhosis; Male; Metformi

1967
Fibrinolytic activity and haemagglutination inhibition immunoassays.
    Scandinavian journal of haematology, 1970, Volume: 7, Issue:4

    Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi

1970
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
    Scandinavian journal of haematology, 1969, Volume: 6, Issue:6

    Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu

1969
[Effect of the peroral antidiabetic "Glucophage" on the glucose tolerance test in liver cirrhosis].
    Casopis lekaru ceskych, 1969, Jun-20, Volume: 108, Issue:26

    Topics: Glucose Tolerance Test; Humans; Injections, Intravenous; Liver Cirrhosis; Metformin; Methods

1969